Clinical trials: Recurrence Hepatocellular Carcinoma
Hepatocellular Carcinoma
Assess Efficacy and Safety of Durvalumab Alone or Combined With Bevacizumab in High Risk of Recurrence HCC Patients After Curative Treatment
A global study to assess the efficacy and safety of durvalumab in combination with bevacizumab or durvalumab alone in patients with hepatocellular carcinoma who are at high risk of recurrence.
- Trial name
- EMERALD-2 (NCT03847428)
- Testing
- Durvalumab, Bevacizumab
- Where
- 217 sites in United States, Australia and 22 more
- Volunteers
- 908 people
- Sponsor
- AstraZeneca
Hepatocellular Carcinoma (HCC) Prognosis, Contrast-enhanced Ultrasound
A Comparative Study on the Diagnostic Efficacy of Ultrasound Contrast LI-RADS Grading and the German ESCULAP Standards for the Diagnosis of Recurrent Hepatic Mass Lesions After Hepatocellular Carcinoma Surgery
Hepatocellular carcinoma (HCC) is the sixth most common malignant tumor worldwide, with a significantly increased incidence among patients with liver diseases.
- Trial name
- NCT07600346
- Testing
- Contrast-Enhanced Ultrasound
- Volunteers
- 105 people
- Sponsor
- The First Hospital of Jilin University
HCC
A Study of AK112, a PD-1/ VEGF Bispecific Antibody, for Resectable Hepatocellular Carcinoma With High Recurrence Risk
This study is a single-arm, open-label study. To assess the efficacy and safety of AK112 therapy in patients with resectable hepatocellular carcinoma at high risk of recurrence.
- Trial name
- NCT06930573
- Testing
- AK112
- Where
- China
- Volunteers
- 30 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Hepatocellular Carcinoma, Adjuvant Therapy
A Study to Evaluate TACE Sequential Tislelizumab as Adjuvant Therapy in Participants With HCC at High Risk of Recurrence After Curative Resection
This is an open label, multi-center, phaseⅡstudy to evaluate the efficacy and safety of TACE sequential tislelizumab as adjuvant therapy in hepatocellular carcinoma (HCC) patients who are at high risk of recurrence after curative…
- Trial name
- NCT04981665
- Testing
- Tislelizumab, TACE
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Zhejiang University
Hepatocellular Carcinoma
Toripalimab or Placebo as Adjuvant Therapy in Hepatocellular Carcinoma After Radical Resection
This study will investigate if Toripalimab (A PD-1 Inhibitor) will improve recurrence-free survival (RFS) compared to placebo in participants with HCC and are at high risk of recurrence after complete resection with no residual…
- Trial name
- JUPITER 04 (NCT03859128)
- Testing
- TORIPALIMAB INJECTION(JS001 )
- Where
- China
- Volunteers
- 427 people
- Sponsor
- Shanghai Junshi Bioscience Co., Ltd.
Cancer
PV701 in Treating Patients With Advanced or Recurrent Peritoneal Cancer
RATIONALE: PV701 may be able to kill tumor cells while leaving normal cells undamaged. PURPOSE: Phase I trial to study the effectiveness of PV701 in treating patients who have advanced or recurrent ovarian epithelial, fallopian…
- Trial name
- NCT00055705
- Testing
- PV701
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hepatocellular Carcinoma
Sequential FOLFOX-HAIC-TACE Plus Sintilimab-Bevacizumab Neoadjuvant Therapy Versus Direct Resection in Resectable High-Risk Recurrence Hepatocellular Carcinoma
This study is designed to evaluate the efficacy and safety of sintilimab-bevacizumab doublet combined with FOLFOX-HAIC and TACE as the perioperative adjuvant therapy in surgical resection to hepatocellular carcinoma with…
- Trial name
- NCT07522411
- Testing
- FOLFOX regimen, Immunotherapy, targeted therapy
- Volunteers
- 100 people
- Sponsor
- BinYong Liang
Liver Cancer
Sunitinib in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00514228
- Testing
- sunitinib malate
- Where
- Switzerland
- Volunteers
- 45 people
- Sponsor
- Swiss Cancer Institute
Hepatocellular Carcinomas
Multipolar Radiofrequency Ablation for Hepatocellular Carcinoma Using Extra Nodular Versus Intranodular Technique
The primary purpose of the trial is to demonstrate that at least a 40% drop of recurrence rate can be achieve in hepatocellular carcinoma patients treated with no touch multipolar radiofrequency ablation technique compared to…
- Trial name
- ARMCENVIN (NCT01008657)
- Testing
- Radiofrequency ablation
- Where
- France
- Volunteers
- 216 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Hepatocellular Carcinoma, Liver Neoplasms
Enhanced Radiofrequency Ablation for Recurrent HCC Post-TACE Using Twin Internally Cooled-Perfusion Electrodes
This single-center, prospective study evaluates the therapeutic outcomes of saline-augmented bipolar radiofrequency ablation (RFA) with twin internally cooled-perfusion (TICP) electrodes for treating recurrent hepatocellular…
- Trial name
- ERFA (NCT07192172)
- Testing
- Bipolar radiofrequency ablation using twin internally cooled perfusion electrodes
- Where
- South Korea
- Volunteers
- 100 people
- Sponsor
- Seoul National University Hospital
Extrahepatic Bile Duct Cancer, Gallbladder Cancer
Liposomal Doxorubicin in Treating Patients With Liver or Bile Duct Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of liposomal doxorubicin in treating patients with liver…
- Conditions
- Extrahepatic Bile Duct Cancer, Gallbladder Cancer, Liver Cancer
- Trial name
- NCT00003296
- Testing
- filgrastim, pegylated liposomal doxorubicin hydrochloride
- Where
- 2 sites in United States
- Volunteers
- 26 people
- Sponsor
- Brown University
Colorectal Cancer, Islet Cell Tumor
Isolated Hepatic Perfusion With Melphalan in Treating Patients With Primary Unresectable Liver Cancer or Liver Metastases
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
- Conditions
- Colorectal Cancer, Islet Cell Tumor, Liver Cancer, Metastatic Cancer
- Trial name
- NCT00019786
- Testing
- isolated perfusion, melphalan, conventional surgery
- Where
- United States
- Volunteers
- 67 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Hepatocellular,Carcinoma
Study of Tyroserleutide for Injection in Hepatocellular Carcinoma (HCC) Patients
This is a randomized, double-blinded, placebo-controlled, multi-center Clinical Trial. Patients with no tumor lesions one month after resection of hepatocellular carcinoma will be randomized in a 1:1 ratio to 1 of the 2 treatment…
- Trial name
- NCT01489566
- Testing
- Tyroserleutide for injection ,chemotherapy(mitomycin, and Fluorouracil )
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Shenzhen Kangzhe Pharmaceutical Co., Ltd.
HCC
Artificial Intelligence and Hepatocellular Carcinoma
To identify new relevant biomarkers for HCC patients and their risk of recurrence. Radiomics data and computer-vision data will be explored for their ability to predict the presence of particular pathological signs of…
- Trial name
- ARTIHCC (NCT05637788)
- Testing
- CT Scan Radiomics Features Extraction
- Where
- Italy
- Volunteers
- 535 people
- Sponsor
- Humanitas Clinical and Research Center
Hepatocellular Carcinoma
A Study to Evaluate C-CAR031 in Glypican-3 (GPC3)+ Advanced/Recurrent Hepatocellular Carcinoma (HCC)
This single-arm, open-label multicenter Phase I/II study will evaluate the safety, tolerability, anti-tumor activity, pharmacokinetics (PK), pharmacodynamics (PD), and immunogenicity of C-CAR031 in adult participants with GPC3+…
- Trial name
- NCT06590246
- Testing
- Armored and GPC3-targeted autologous CAR T-cell
- Where
- 2 sites in China
- Volunteers
- 121 people
- Sponsor
- Shanghai AbelZeta Ltd.
Liver Cancer, Recurrence
Factors Influencing the 3-Year Recurrence of Liver Carcinoma After Surgery
Objective: 1. To study the factors that influence the 3- year recurrence of liver carcinoma after surgery 2. To study the related factors affecting recurrence of liver carcinoma after surgery
- Trial name
- NCT02941861
- Testing
- Recurrence Rate of HCC after surgery, Recurrence Rate of CCA after surgery
- Volunteers
- 67 people
- Sponsor
- Ruechuta Molek
Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer
AZD2171 in Treating Patients With Locally Advanced Unresectable or Metastatic Liver Cancer
This phase II trial is studying how well AZD2171 works in treating patients with locally advanced unresectable or metastatic liver cancer.
- Conditions
- Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
- Trial name
- NCT00427973
- Testing
- cediranib maleate, laboratory biomarker analysis, computed tomography
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Extrahepatic Bile Duct Adenocarcinoma, Biliary Type, Gallbladder Adenocarcinoma, Biliary Type
Guadecitabine and Durvalumab in Treating Patients With Advanced Liver, Pancreatic, Bile Duct, or Gallbladder Cancer
This phase Ib trial studies the side effects and best dose of guadecitabine and how well it works when given together with durvalumab in treating patients with liver, pancreatic, bile duct, or gallbladder cancer that has spread…
- Conditions
- Extrahepatic Bile Duct Adenocarcinoma, Biliary Type, Gallbladder Adenocarcinoma, Biliary Type, Metastatic Pancreatic Adenocarcinoma, Recurrent Cholangiocarcinoma
- Trial name
- NCT03257761
- Testing
- Durvalumab, Guadecitabine
- Where
- 3 sites in United States
- Volunteers
- 55 people
- Sponsor
- University of Southern California
Carcinoma, Hepatocellular
Sorafenib as Adjuvant Treatment in the Prevention Of Recurrence of Hepatocellular Carcinoma (STORM)
To evaluate efficacy and safety of sorafenib versus placebo in the adjuvant treatment of Hepatocellular Carcinoma (HCC) after potentially curative treatment (surgical resection or local ablation).
- Trial name
- STORM (NCT00692770)
- Testing
- Nexavar (Sorafenib, BAY43-9006)
- Where
- 199 sites in United States, Argentina and 26 more
- Volunteers
- 1,114 people
- Sponsor
- Bayer
Hepatocellular Carcinoma (HCC)
Circulating Tumor Mitochondrial DNA (ct-mtDNA) As a Biomarker for Hepatocellular Carcinoma Recurrence Surveillance
This is a prospective, observational, single-center study. The purpose of this study is to evaluate the efficacy of circulating tumor mitochondrial DNA (ct-mtDNA) in plasma as a biomarker for minimal residual disease (MRD)…
- Trial name
- CCGLC-015 (NCT06653062)
- Testing
- Plasma and Tumor Tissue Mitochondrial DNA (mtDNA) Mutation Analysis
- Where
- China
- Volunteers
- 50 people
- Sponsor
- Tongji Hospital